{"protocolSection":{"identificationModule":{"nctId":"NCT03095599","orgStudyIdInfo":{"id":"IVACFLU-S 0203"},"secondaryIdInfos":[{"id":"CVIA 051","type":"OTHER","domain":"PATH"}],"organization":{"fullName":"Institute of Vaccines and Medical Biologicals, Vietnam","class":"INDUSTRY"},"briefTitle":"Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3","officialTitle":"A Phase 2/3 Double Blinded, Randomized, Placebo-Controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced by IVAC","acronym":"IVACFLUS-0203"},"statusModule":{"statusVerifiedDate":"2019-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-03-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-10-05","type":"ACTUAL"},"completionDateStruct":{"date":"2017-10-05","type":"ACTUAL"},"studyFirstSubmitDate":"2017-03-13","studyFirstSubmitQcDate":"2017-03-23","studyFirstPostDateStruct":{"date":"2017-03-29","type":"ACTUAL"},"resultsFirstSubmitDate":"2018-10-24","resultsFirstSubmitQcDate":"2019-05-12","resultsFirstPostDateStruct":{"date":"2019-07-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-05-12","lastUpdatePostDateStruct":{"date":"2019-07-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Institute of Vaccines and Medical Biologicals, Vietnam","class":"INDUSTRY"},"collaborators":[{"name":"Pasteur Institute, Ho Chi Minh City","class":"OTHER_GOV"},{"name":"PATH","class":"OTHER"},{"name":"Quintiles, Inc.","class":"INDUSTRY"},{"name":"World Health Organization","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Phase 2/3 study assessed whether a single dose of seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) is safe and well-tolerated in adults 18 to 60 years of age; and whether it will induce immune responses to each of the 3 vaccine antigens to meet 1 or both age group-specific Vietnam Ministry of Health (MOH) licensure requirements.","detailedDescription":"Seasonal influenza viruses circulate widely and cause disease in humans every year. Seasonal influenza viruses evolve continuously, which means that people can get infected multiple times throughout their lives. Therefore the components of seasonal influenza vaccines are reviewed frequently (currently biannually) and updated periodically to ensure continued effectiveness of the vaccines. The World Health Organization (WHO) recommended that influenza vaccines for use in the 2016-2017 northern hemisphere influenza season contain the following viruses:\n\n* NYMC BX-35 reassortant of B/Brisbane/60/2008 (B)\n* NYMC X-179A reassortant of A/California/7/2009 (H1N1)\n* NYMC X-263B reassortant of H3/A/Hong Kong/4801/2014 (H3N2)\n\nAmong circulating influenza B viruses, there were 2 distinct lineages. The B/Brisbane/60/2008-like viruses were from the influenza B/Victoria lineage and represented the predominant circulating influenza B virus. The preclinical evaluation was conducted with all 3 lots of seasonal vaccine used in the Phase 1 study.The Phase 1 study of the IVACFLU-S that was completed in March 2016 identified no safety concerns and demonstrated the vaccine to be highly immunogenic. Given the promising findings, the current study proposed to expand on the safety data of the vaccine, to confirm the immunological findings, and by including individuals up to age 60 to seek regulatory approval for indication in nonelderly adults based on the Vietnam MOH Guidance on Clinical Trial of Influenza Vaccine serological criteria for assessing seasonal influenza.\n\nPhase 2 was conducted at 1 site (District Health Center of Ben Luc, Long An, Vietnam). Subjects were from two age groups: 18-45 years and 46-60 years. Vaccine safety was determined by the Protocol Safety Review Team (PSRT) and approved by Vietnam Ministry of Health (MOH) before starting Phase 3.\n\nPhase 3 was conducted at 2 sites: District Health Center (DHC) of Ben Luc, Long An, Vietnam; and DHC of Long Thanh, Dong Nai. Subjects were from two age groups: 18-45 years and 46-60 years. Both safety and immunogenicity were assessed."},"conditionsModule":{"conditions":["Influenza, Human"],"keywords":["Influenza","Vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":889,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vaccine","type":"EXPERIMENTAL","description":"Received one dose of IVACFLU-S vaccine intramuscularly.","interventionNames":["Biological: IVACFLU-S"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Received one dose of placebo intramuscularly.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"IVACFLU-S","description":"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains\n\n* NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)\n* NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA\n* NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA","armGroupLabels":["Vaccine"]},{"type":"OTHER","name":"Placebo","description":"Phosphate buffered saline with pH 7.2; 0.5 ml/per dose","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE)","description":"Solicited local AEs were assessed by study staff 30 minutes after vaccination.","timeFrame":"Within 30 minutes of vaccination"},{"measure":"Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE)","description":"Solicited systemic AEs were assessed by study staff 30 minutes after vaccination.","timeFrame":"Within 30 minutes of vaccination"},{"measure":"Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE), by Severity","description":"Solicited local AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days by the subjects. Subjects were provided a thermometer, ruler and a diary to record the presence or absence of solicited AEs, severity of the solicited AE and use of concomitant medication. AEs were graded as follows:\n\n* Mild: Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.\n* Moderate: Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated.\n* Severe: Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.\n* Life-threatening: Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.","timeFrame":"Day 1 to Day 7"},{"measure":"Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE), by Severity","description":"Solicited systemic AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days by the subjects. Subjects were provided a thermometer, ruler and a diary to record the presence or absence of solicited AEs, severity of the solicited AE and use of concomitant medication. AEs were graded as follows:\n\n* Mild: Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.\n* Moderate: Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated.\n* Severe: Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.\n* Life-threatening: Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.","timeFrame":"Day 1 to Day 7"},{"measure":"Number and Percentage of Subjects Experiencing Fever","description":"Subjects reporting body temperature by maximum severity; Grade 0: \\<38°C, Grade 1: 38.0 - \\<38.6°C, Grade 2: 38.6 - \\<39.3°C, Grade 3: 39.3 - \\<40.0°C, Grade 4: \\>= 40.0°C","timeFrame":"Day 1 to Day 7"},{"measure":"Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)","description":"Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a \"solicited AE\" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE. The clinician determined whether there was a reasonable possibility that the investigational product(s) caused or contributed to an AE. The following guidelines were used:\n\n* Related: There is a reasonable possibility that the study vaccine caused the AE. \"Reasonable possibility\" means that there is evidence to suggest a causal relationship between the study product and the AE.\n* Not Related: There is not a reasonable possibility that the administration of the study product caused the event.","timeFrame":"Day 1 to Day 21"},{"measure":"Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)","description":"Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a \"solicited AE\" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE. The clinician determined whether there was a reasonable possibility that the investigational product(s) caused or contributed to an AE. The following guidelines were used:\n\n* Related: There is a reasonable possibility that the study vaccine caused the AE. \"Reasonable possibility\" means that there is evidence to suggest a causal relationship between the study product and the AE.\n* Not Related: There is not a reasonable possibility that the administration of the study product caused the event.","timeFrame":"Day 1 to Day 91"},{"measure":"Number and Percentage of Subjects With Seroconversion of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens, Overall and by Age Group","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.\n\nSeroconversion is defined as a serum HAI antibody titer meeting the following criteria:\n\n* pre-vaccination titer \\< 1:10 and a post-vaccination titer measured on Day 22 of ≥ 1:40, or\n* pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination measured on Day 22","timeFrame":"Day 1, Day 22"},{"measure":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22, Overall and by Age Group","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 1, Day 22"},{"measure":"Geometric Mean Fold Change of Serum Hemagglutination Inhibition (HAI) Antibody Titer, Overall and by Age Group","description":"Fold change in titer between Day 1 and Day 22. Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 1, Day 22"}],"secondaryOutcomes":[{"measure":"Number and Percentage of Subjects With at Least a 4-fold Increase in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 22"},{"measure":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: All Subjects","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H1N1). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 1, Day 22"},{"measure":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 18-45","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 1, Day 22"},{"measure":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 46-60","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 1, Day 22"},{"measure":"Geometric Mean Fold Change in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","timeFrame":"Day 1, Day 22"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Aged 18 through 60 years on the day of screening/enrollment.\n* Literate (by self-report) and willing to provide written informed consent.\n* Able to attend all scheduled visits and to comply with all study procedures.\n* Healthy or medically stable, as established by medical history and physical examination. For individuals with medical conditions, symptoms/signs, if present must be stable under controlled or unchanged for the past 3 months. If medication is used to treat the condition, the medication dose must have been stable for at least 1 month preceding vaccination.\n\nFor female subjects:\n\n* Not breastfeeding or pregnant (based on negative urine pregnancy test) or plan to become pregnant up to Day 22. Women who are not surgically sterile (hysterectomy or tubal ligation) or post-menopausal for more than 1 year must have negative pregnancy test and, be willing to utilize reliable birth control measures (intrauterine device, hormonal contraception, condom or diaphragm with spermicide) through the Day 22 visit.\n\nExclusion criteria:\n\n* Current or recent (within 2 weeks of enrollment) acute severe illness with or without fever.\n* Participation in another clinical study involving any therapy within the previous 3 months or planned enrollment in such a study during the period of this study.\n* Receipt of any non-study vaccine within 4 weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 22 visit.\n* Received seasonal influenza vaccine in last 6 months\n* Receipt of immune globulin or other blood products within 3 months prior to study enrollment or planned receipt of such products prior to the Day 22 visit.\n* Known or suspected congenital or acquired immunodeficiency.\n* Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within 6 months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, ≥ 0.5 mg/kg/day; topical steroids are allowed).\n* Unstable illness by history or physical examination that in the opinion of the Investigator, might interfere with the conduct or results of the study or pose additional risk to the subject.\n* Hypersensitivity after previous administration of any vaccine.\n* Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein, and rubber (from the vaccine vial stoppers).\n* Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion.\n* Known active tuberculosis or symptoms of active tuberculosis, regardless of cause (self-report).\n* Current alcohol or drug addiction that in the opinion of the Investigator, might interfere with the ability to comply with study procedures.\n* History of Guillain-Barré Syndrome\n* Neoplastic disease or any hematologic malignancy.\n* Any condition that, in the opinion of the Investigator, would increase the health risk to the subject if he/she participates in the study, or would interfere with the evaluation of the study objectives.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Phan Cong Hung, MD","affiliation":"Pasteur Institute, Ho Chi Minh City","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Pasteur Institute, Ho Chi Minh City","city":"Ho Chi Minh City","country":"Vietnam","geoPoint":{"lat":10.82302,"lon":106.62965}}]},"referencesModule":{"references":[{"pmid":"31070986","type":"DERIVED","citation":"Lan PT, Toan NT, Thang HA, Thang TC, Be LV, Thai DH, Huong VM, Nga NT, Tang Y, Holt R, Francesco BS, Flores J, Tewari T. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam. Hum Vaccin Immunother. 2019;15(12):2933-2939. doi: 10.1080/21645515.2019.1613127. Epub 2019 Jun 20."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Phase 2 was conducted at the District Health Center (DHC) of Ben Luc, Long An Province and involved 252 subjects. After positive safety review of Day 8 data, Phase 3 was at 2 sites: the DHC of Ben Luc, Long An Province and the DHC of Long Thanh, Dong Nai Province.\n\nIn total, of the 1399 subjects who were screened, 888 subjects were rand","groups":[{"id":"FG000","title":"Vaccine","description":"IVACFLU-S: Trivalent inactivated split virion influenza vaccine"},{"id":"FG001","title":"Placebo","description":"PBS with pH 7.2; 0.5 ml/per dose"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"741"},{"groupId":"FG001","numSubjects":"148"}]},{"type":"Withdrawal Before Vaccination","comment":"Voluntary withdrawal.","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"740"},{"groupId":"FG001","numSubjects":"148"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"738"},{"groupId":"FG001","numSubjects":"148"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal prior to vaccination","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Vaccine","description":"IVACFLU-S: Trivalent inactivated split virion influenza vaccine"},{"id":"BG001","title":"Placebo","description":"PBS with pH 7.2; 0.5 ml/per dose"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"740"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"888"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42.8","lowerLimit":"18","upperLimit":"60"},{"groupId":"BG001","value":"42.8","lowerLimit":"18","upperLimit":"60"},{"groupId":"BG002","value":"42.8","lowerLimit":"18","upperLimit":"60"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"431"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"520"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"309"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"368"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Kinh","categories":[{"measurements":[{"groupId":"BG000","value":"735"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"883"}]}]},{"title":"Khmer","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"Hoa","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Vietnam","categories":[{"measurements":[{"groupId":"BG000","value":"740"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"888"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE)","description":"Solicited local AEs were assessed by study staff 30 minutes after vaccination.","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 30 minutes of vaccination","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Induration","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Redness","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Pain","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"}]}]},{"title":"Swelling","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Tenderness","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"1"}]}]},{"title":"No report of solicited local AE","categories":[{"measurements":[{"groupId":"OG000","value":"711"},{"groupId":"OG001","value":"147"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE)","description":"Solicited systemic AEs were assessed by study staff 30 minutes after vaccination.","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Within 30 minutes of vaccination","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Chills","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Fatigue/Malaise","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Generalized muscle aches","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}]},{"title":"Headaches","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Joint aches","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"No report of solicited systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"733"},{"groupId":"OG001","value":"148"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE), by Severity","description":"Solicited local AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days by the subjects. Subjects were provided a thermometer, ruler and a diary to record the presence or absence of solicited AEs, severity of the solicited AE and use of concomitant medication. AEs were graded as follows:\n\n* Mild: Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.\n* Moderate: Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated.\n* Severe: Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.\n* Life-threatening: Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 7","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Hardness","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"0"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"716"},{"groupId":"OG001","value":"148"}]}]},{"title":"Pain","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"405"},{"groupId":"OG001","value":"25"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"1"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"122"}]}]},{"title":"Redness","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"721"},{"groupId":"OG001","value":"147"}]}]},{"title":"Swelling","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"1"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"714"},{"groupId":"OG001","value":"147"}]}]},{"title":"Tenderness","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"441"},{"groupId":"OG001","value":"30"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"2"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"116"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Solicited Systemic Adverse Events (AE), by Severity","description":"Solicited systemic AEs were assessed by study staff 30 minutes after vaccination then daily for 7 days by the subjects. Subjects were provided a thermometer, ruler and a diary to record the presence or absence of solicited AEs, severity of the solicited AE and use of concomitant medication. AEs were graded as follows:\n\n* Mild: Mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated.\n* Moderate: Moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated.\n* Severe: Severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated.\n* Life-threatening: Potentially life-threatening symptoms causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death.","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 7","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Chills","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"10"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"695"},{"groupId":"OG001","value":"135"}]}]},{"title":"Fatigue/Malaise","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"18"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"8"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"598"},{"groupId":"OG001","value":"121"}]}]},{"title":"Generalized muscle aches","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"114"},{"groupId":"OG001","value":"14"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"1"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"603"},{"groupId":"OG001","value":"132"}]}]},{"title":"Headaches","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"23"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"4"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"619"},{"groupId":"OG001","value":"119"}]}]},{"title":"Joint aches","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"11"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"682"},{"groupId":"OG001","value":"136"}]}]},{"title":"Nausea","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"723"},{"groupId":"OG001","value":"143"}]}]},{"title":"Vomiting","categories":[{"title":"Mild","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]},{"title":"Moderate","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]},{"title":"Severe","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Life threatening","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]},{"title":"None reported","measurements":[{"groupId":"OG000","value":"734"},{"groupId":"OG001","value":"148"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Fever","description":"Subjects reporting body temperature by maximum severity; Grade 0: \\<38°C, Grade 1: 38.0 - \\<38.6°C, Grade 2: 38.6 - \\<39.3°C, Grade 3: 39.3 - \\<40.0°C, Grade 4: \\>= 40.0°C","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 7","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"categories":[{"title":"Grade 0","measurements":[{"groupId":"OG000","value":"729"},{"groupId":"OG001","value":"146"}]},{"title":"Grade 1","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]},{"title":"Grade 2","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]},{"title":"Grade 3","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]},{"title":"Grade 4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Unsolicited Adverse Events (AE)","description":"Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a \"solicited AE\" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE. The clinician determined whether there was a reasonable possibility that the investigational product(s) caused or contributed to an AE. The following guidelines were used:\n\n* Related: There is a reasonable possibility that the study vaccine caused the AE. \"Reasonable possibility\" means that there is evidence to suggest a causal relationship between the study product and the AE.\n* Not Related: There is not a reasonable possibility that the administration of the study product caused the event.","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 21","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"At least one unsolicited AE","categories":[{"measurements":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"17"}]}]},{"title":"At least one vaccine-related unsolicited AE","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"At least one severe unsolicited AE","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"At least one life threatening unsolicited AE","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Subjects requiring treatment during the study","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects Experiencing Unsolicited Serious Adverse Events (SAE)","description":"Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a \"solicited AE\" (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE. The clinician determined whether there was a reasonable possibility that the investigational product(s) caused or contributed to an AE. The following guidelines were used:\n\n* Related: There is a reasonable possibility that the study vaccine caused the AE. \"Reasonable possibility\" means that there is evidence to suggest a causal relationship between the study product and the AE.\n* Not Related: There is not a reasonable possibility that the administration of the study product caused the event.","populationDescription":"All recipients of the vaccine in Phases 2 and 3","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 to Day 91","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"740"},{"groupId":"OG001","value":"148"}]}],"classes":[{"title":"Related to vaccine","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Not related to vaccine","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number and Percentage of Subjects With Seroconversion of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens, Overall and by Age Group","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.\n\nSeroconversion is defined as a serum HAI antibody titer meeting the following criteria:\n\n* pre-vaccination titer \\< 1:10 and a post-vaccination titer measured on Day 22 of ≥ 1:40, or\n* pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination measured on Day 22","populationDescription":"Phase 3 participants who were participated in the study through at least day 22, overall and by age group.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"classes":[{"title":"Overall: A/H1N1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall: A/H3N2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall: B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"1"}]}]},{"title":"Ages 18-45: A/H1N1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ages 18-45: AH3N2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ages 18-45: B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ages 46-60: A/H1N1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ages 46-60: A/H3N2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"0"}]}]},{"title":"Ages 46-60: B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22, Overall and by Age Group","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were participated in the study through at least day 22, overall and by age group.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"classes":[{"title":"Overall: A/H1N1: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.93","lowerLimit":"8.593","upperLimit":"11.465"},{"groupId":"OG001","value":"13.51","lowerLimit":"9.288","upperLimit":"19.665"}]}]},{"title":"Overall: A/H1N1: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"130.48","lowerLimit":"107.898","upperLimit":"157.78"},{"groupId":"OG001","value":"13.46","lowerLimit":"9.438","upperLimit":"19.192"}]}]},{"title":"Overall: A/H3N2: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.92","lowerLimit":"11.256","upperLimit":"14.831"},{"groupId":"OG001","value":"12.65","lowerLimit":"8.836","upperLimit":"18.115"}]}]},{"title":"Overall: A/H3N2: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"153.12","lowerLimit":"127.996","upperLimit":"183.17"},{"groupId":"OG001","value":"12.65","lowerLimit":"8.859","upperLimit":"18.068"}]}]},{"title":"Overall: B: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.17","lowerLimit":"6.620","upperLimit":"7.756"},{"groupId":"OG001","value":"6.35","lowerLimit":"5.468","upperLimit":"7.379"}]}]},{"title":"Overall: B: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.04","lowerLimit":"35.654","upperLimit":"49.570"},{"groupId":"OG001","value":"6.79","lowerLimit":"5.580","upperLimit":"8.251"}]}]},{"title":"Ages 18-45: A/H1N1: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.65","lowerLimit":"10.102","upperLimit":"15.837"},{"groupId":"OG001","value":"15.49","lowerLimit":"8.399","upperLimit":"28.553"}]}]},{"title":"Ages 18-45: A/H1N1: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"149.19","lowerLimit":"119.134","upperLimit":"186.81"},{"groupId":"OG001","value":"15.74","lowerLimit":"8.732","upperLimit":"28.386"}]}]},{"title":"Ages 18-45: A/H3N2: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.16","lowerLimit":"13.008","upperLimit":"20.072"},{"groupId":"OG001","value":"21.36","lowerLimit":"11.900","upperLimit":"38.359"}]}]},{"title":"Ages 18-45: A/H3N2: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"145.26","lowerLimit":"114.633","upperLimit":"184.07"},{"groupId":"OG001","value":"22.26","lowerLimit":"12.528","upperLimit":"39.569"}]}]},{"title":"Ages 18-45: B: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.48","lowerLimit":"5.915","upperLimit":"7.108"},{"groupId":"OG001","value":"6.20","lowerLimit":"5.273","upperLimit":"7.282"}]}]},{"title":"Ages 18-45: B: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.18","lowerLimit":"30.703","upperLimit":"47.469"},{"groupId":"OG001","value":"6.62","lowerLimit":"5.278","upperLimit":"8.302"}]}]},{"title":"Ages 46-60: A/H1N1: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.81","lowerLimit":"6.569","upperLimit":"9.278"},{"groupId":"OG001","value":"11.79","lowerLimit":"7.278","upperLimit":"19.112"}]}]},{"title":"Ages 46-60: A/H1N1: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114.26","lowerLimit":"84.025","upperLimit":"155.382"},{"groupId":"OG001","value":"11.51","lowerLimit":"7.418","upperLimit":"17.846"}]}]},{"title":"Ages 46-60: A/H3N2: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.35","lowerLimit":"8.790","upperLimit":"12.193"},{"groupId":"OG001","value":"7.49","lowerLimit":"5.447","upperLimit":"10.304"}]}]},{"title":"Ages 46-60: A/H3N2: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"161.33","lowerLimit":"122.860","upperLimit":"211.83"},{"groupId":"OG001","value":"7.19","lowerLimit":"5.363","upperLimit":"9.635"}]}]},{"title":"Ages 46-60: B: Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.91","lowerLimit":"6.964","upperLimit":"8.986"},{"groupId":"OG001","value":"6.51","lowerLimit":"4.979","upperLimit":"8.514"}]}]},{"title":"Ages 46-60: B: Day 22","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.25","lowerLimit":"36.051","upperLimit":"59.341"},{"groupId":"OG001","value":"6.96","lowerLimit":"4.950","upperLimit":"9.773"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Change of Serum Hemagglutination Inhibition (HAI) Antibody Titer, Overall and by Age Group","description":"Fold change in titer between Day 1 and Day 22. Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were participated in the study through at least day 22, overall and by age group.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"fold change","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"classes":[{"title":"Overall: A/H1N1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.15","lowerLimit":"10.623","upperLimit":"16.268"},{"groupId":"OG001","value":"1.00","lowerLimit":"0.909","upperLimit":"1.091"}]}]},{"title":"Overall: A/H3N2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.85","lowerLimit":"9.762","upperLimit":"14.388"},{"groupId":"OG001","value":"1.00","lowerLimit":"0.939","upperLimit":"1.065"}]}]},{"title":"Overall: B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.87","lowerLimit":"4.987","upperLimit":"6.902"},{"groupId":"OG001","value":"1.07","lowerLimit":"0.895","upperLimit":"1.275"}]}]},{"title":"Ages 18-45: A/H1N1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.79","lowerLimit":"8.832","upperLimit":"15.752"},{"groupId":"OG001","value":"1.02","lowerLimit":"0.852","upperLimit":"1.213"}]}]},{"title":"Ages 18-45: AH3N2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.99","lowerLimit":"6.878","upperLimit":"11.750"},{"groupId":"OG001","value":"1.04","lowerLimit":"0.935","upperLimit":"1.162"}]}]},{"title":"Ages 18-45: B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.89","lowerLimit":"4.694","upperLimit":"7.385"},{"groupId":"OG001","value":"1.07","lowerLimit":"0.852","upperLimit":"1.340"}]}]},{"title":"Ages 46-60: A/H1N1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.64","lowerLimit":"10.669","upperLimit":"20.078"},{"groupId":"OG001","value":"0.98","lowerLimit":"0.908","upperLimit":"1.048"}]}]},{"title":"Ages 46-60: AH3N2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.58","lowerLimit":"11.839","upperLimit":"20.512"},{"groupId":"OG001","value":"0.96","lowerLimit":"0.895","upperLimit":"1.029"}]}]},{"title":"Ages 46-60: B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.85","lowerLimit":"4.615","upperLimit":"7.407"},{"groupId":"OG001","value":"1.07","lowerLimit":"0.797","upperLimit":"1.433"}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Subjects With at Least a 4-fold Increase in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were participated in the study through at least day 22, overall and by age group.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"classes":[{"title":"Overall A/H1N1; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall for A/H1N1; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall A/H3N2; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall A/H3N2; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"0"}]}]},{"title":"Overall B; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"1"}]}]},{"title":"Overall B; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age18-45 A/H1N1; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 18-45 A/H1N1; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age18-45 A/H3N2; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 18-45 A/H3N2; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age18-45 B; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 18-45 B; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 46-60 A/H1N1; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 46-60 A/H1N1; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 46-60 A/H3N2; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 46-60 A/H3N2; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"0"}]}]},{"title":"Age 46-60 B; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"1"}]}]},{"title":"Age 46-60 B; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: All Subjects","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H1N1). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were participated in the study through at least day 22.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"titer","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"IVACFLU-S: Trivalent inactivated split virion influenza vaccine"},{"id":"OG001","title":"Placebo","description":"PBS with pH 7.2; 0.5 ml/per dose"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"classes":[{"title":"A/H1N1, Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H1N1, Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.40","spread":"2.55"},{"groupId":"OG001","value":"33.37","spread":"2.76"}]}]},{"title":"A/H1N1, Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.78","spread":"4.88"},{"groupId":"OG001","value":"5.45","spread":"1.31"}]}]},{"title":"A/H1N1, Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"204.75","spread":"2.27"},{"groupId":"OG001","value":"30.60","spread":"2.69"}]}]},{"title":"A/H3N2 Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H3N2 Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.49","spread":"2.16"},{"groupId":"OG001","value":"32.01","spread":"2.60"}]}]},{"title":"A/H3N2 Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.17","spread":"4.72"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H3N2 Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"215.97","spread":"2.65"},{"groupId":"OG001","value":"32.01","spread":"2.54"}]}]},{"title":"B, Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"B, Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.64","spread":"1.63"},{"groupId":"OG001","value":"13.66","spread":"1.56"}]}]},{"title":"B, Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.10","spread":"3.45"},{"groupId":"OG001","value":"5.95","spread":"1.80"}]}]},{"title":"B, Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"67.61","spread":"2.71"},{"groupId":"OG001","value":"10.35","spread":"1.78"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 18-45","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were age 18-45 and participated in the study through at least day 22.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"titer","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"21"}]}],"classes":[{"title":"A/H1N1, Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H1N1, Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.85","spread":"2.41"},{"groupId":"OG001","value":"43.28","spread":"2.95"}]}]},{"title":"A/H1N1, Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"117.13","spread":"4.11"},{"groupId":"OG001","value":"5.95","spread":"1.45"}]}]},{"title":"A/H1N1, Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"195.73","spread":"2"},{"groupId":"OG001","value":"38.15","spread":"3.29"}]}]},{"title":"A/H3N2 Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H3N2 Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.07","spread":"2.42"},{"groupId":"OG001","value":"38.19","spread":"2.85"}]}]},{"title":"A/H3N2 Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.51","spread":"4.49"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H3N2 Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"188.82","spread":"2.58"},{"groupId":"OG001","value":"40.46","spread":"2.64"}]}]},{"title":"B, Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"B, Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.13","spread":"1.46"},{"groupId":"OG001","value":"10.59","spread":"1.15"}]}]},{"title":"B, Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.97","spread":"3.22"},{"groupId":"OG001","value":"6.02","spread":"1.66"}]}]},{"title":"B, Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.46","spread":"2.59"},{"groupId":"OG001","value":"8.41","spread":"1.53"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22: Subjects Aged 46-60","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were age 46-60 and participated in the study through at least day 22.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"titer","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"21"}]}],"classes":[{"title":"A/H1N1, Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H1N1, Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.10","spread":"2.72"},{"groupId":"OG001","value":"25.73","spread":"2.50"}]}]},{"title":"A/H1N1, Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"88.85","spread":"5.47"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H1N1, Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"220.93","spread":"2.74"},{"groupId":"OG001","value":"24.55","spread":"2.08"}]}]},{"title":"A/H3N2 Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H3N2 Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.37","spread":"1.74"},{"groupId":"OG001","value":"20.59","spread":"1.64"}]}]},{"title":"A/H3N2 Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"103.41","spread":"4.93"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"A/H3N2 Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"258.34","spread":"2.70"},{"groupId":"OG001","value":"17.82","spread":"1.69"}]}]},{"title":"B, Day 1: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"1"},{"groupId":"OG001","value":"5","spread":"1"}]}]},{"title":"B, Day 1: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.74","spread":"1.72"},{"groupId":"OG001","value":"20","spread":"1.63"}]}]},{"title":"B, Day 22: baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.97","spread":"3.75"},{"groupId":"OG001","value":"5.89","spread":"1.96"}]}]},{"title":"B, Day 22: baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"84.41","spread":"2.64"},{"groupId":"OG001","value":"14.14","spread":"2"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Change in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer","description":"Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine (A/H1N1, B, and A/H3N2). This testing was performed by VisMederi SRL laboratory (Siena, Italy), by using a validated assay. Sample collection on Day 1 was prior to administration of study product.","populationDescription":"Phase 3 participants who were participated in the study through at least day 22, overall and by age group.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"fold change","timeFrame":"Day 1, Day 22","groups":[{"id":"OG000","title":"Vaccine","description":"Received one dose of IVACFLU-S vaccine intramuscularly."},{"id":"OG001","title":"Placebo","description":"Received one dose of placebo intramuscularly."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"42"}]}],"classes":[{"title":"Overall A/H1N1; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.96","spread":"4.88"},{"groupId":"OG001","value":"1.09","spread":"1.31"}]}]},{"title":"Overall for A/H1N1; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.52","spread":"3.48"},{"groupId":"OG001","value":"0.92","spread":"1.34"}]}]},{"title":"Overall A/H3N2; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.43","spread":"4.72"},{"groupId":"OG001","value":"1","spread":"1"}]}]},{"title":"Overall A/H3N2; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"21"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.15","spread":"3.30"},{"groupId":"OG001","value":"1","spread":"1"}]}]},{"title":"Overall B; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"32"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.62","spread":"3.45"},{"groupId":"OG001","value":"1.19","spread":"1.80"}]}]},{"title":"Overall B; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":"2.89"},{"groupId":"OG001","value":"0.76","spread":"1.38"}]}]},{"title":"Age18-45 A/H1N1; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.43","spread":"4.11"},{"groupId":"OG001","value":"1.19","spread":"1.45"}]}]},{"title":"Age 18-45 A/H1N1; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.46","spread":"3.20"},{"groupId":"OG001","value":"0.88","spread":"1.43"}]}]},{"title":"Age18-45 A/H3N2; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.70","spread":"4.49"},{"groupId":"OG001","value":"1.00","spread":"1.00"}]}]},{"title":"Age 18-45 A/H3N2; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":"3.21"},{"groupId":"OG001","value":"1.06","spread":"1.33"}]}]},{"title":"Age18-45 B; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.99","spread":"3.22"},{"groupId":"OG001","value":"1.20","spread":"1.66"}]}]},{"title":"Age 18-45 B; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":"2.81"},{"groupId":"OG001","value":"0.79","spread":"1.43"}]}]},{"title":"Age 46-60 A/H1N1; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.77","spread":"5.47"},{"groupId":"OG001","value":"1.00","spread":"1.00"}]}]},{"title":"Age 46-60 A/H1N1; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.80","spread":"3.84"},{"groupId":"OG001","value":"0.95","spread":"1.25"}]}]},{"title":"Age 46-60 A/H3N2; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.68","spread":"4.93"},{"groupId":"OG001","value":"1.00","spread":"1.00"}]}]},{"title":"Age 46-60 A/H3N2; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.55","spread":"3.16"},{"groupId":"OG001","value":"0.87","spread":"1.32"}]}]},{"title":"Age 46-60 B; baseline <1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.19","spread":"3.75"},{"groupId":"OG001","value":"1.18","spread":"1.96"}]}]},{"title":"Age 46-60 B; baseline ≥1:10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.36","spread":"2.90"},{"groupId":"OG001","value":"0.71","spread":"1.33"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"22 days for non-serious adverse events; 91 days for serious adverse events.","eventGroups":[{"id":"EG000","title":"Vaccine","description":"IVACFLU-S: Trivalent inactivated split virion influenza vaccine","deathsNumAffected":0,"deathsNumAtRisk":740,"seriousNumAffected":4,"seriousNumAtRisk":740,"otherNumAffected":110,"otherNumAtRisk":740},{"id":"EG001","title":"Placebo","description":"PBS with pH 7.2; 0.5 ml/per dose","deathsNumAffected":0,"deathsNumAtRisk":148,"seriousNumAffected":2,"seriousNumAtRisk":148,"otherNumAffected":17,"otherNumAtRisk":148}],"seriousEvents":[{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":740},{"groupId":"EG001","numAffected":0,"numAtRisk":148}]},{"term":"Limb crushing injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":740},{"groupId":"EG001","numAffected":0,"numAtRisk":148}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":740},{"groupId":"EG001","numAffected":0,"numAtRisk":148}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":740},{"groupId":"EG001","numAffected":0,"numAtRisk":148}]},{"term":"Pharyngitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":740},{"groupId":"EG001","numAffected":1,"numAtRisk":148}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":740},{"groupId":"EG001","numAffected":1,"numAtRisk":148}]}],"otherEvents":[{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Vestibular disorder","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Gastrooesophageal Reflux Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Gingival Swelling","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Injection Site Haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Injection Site Pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Peripheral Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Food Allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Acute Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Gingivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Hordeolum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Viral Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Viral Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Limb Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Blood Pressure Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Muscle fatigue","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Spinal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Intercostal Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Nervousness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Vaginal Haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Productive Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Throat Irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Upper Respiratory Tract Inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Dermatitis Allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Haemorrhage Subcutaneous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Pruritus Generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":740},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":148}]},{"term":"Spondylolisthesis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]},{"term":"Pulmonary Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":740},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":148}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Le Van Be","organization":"IVAC","email":"ivaclevabe@dng.vnn.vn","phone":"(+84 90) 3501529"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP_ICF","hasProtocol":true,"hasSap":true,"hasIcf":true,"label":"Study Protocol, Statistical Analysis Plan, and Informed Consent Form","date":"2017-02-09","uploadDate":"2019-05-10T18:27","filename":"Prot_SAP_ICF_000.pdf","size":13747038}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}